Trellus Health PLC Result of AGM (6331D)
22 6월 2023 - 9:37PM
UK Regulatory
TIDMTRLS
RNS Number : 6331D
Trellus Health PLC
22 June 2023
Trellus Health plc
("Trellus Health" or the "Company")
Result of AGM
LONDON, U.K. AND NEW YORK, U.S. (22 June 2023). Trellus Health
plc (AIM: TRLS), which is commercializing a scientifically
validated, personalized resilience-driven self-management solution
for chronic health conditions at their intersection with mental
health, announces that at the Annual General Meeting ("AGM") held
earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:
In Favour Against Withheld
Resolution Votes % Votes % Votes
----------- -------- -------- ------ ---------
1 43,559,167 100.00% 0 0.00% 1,171
----------- -------- -------- ------ ---------
2 43,391,049 99.95% 21,961 0.05% 147,328
----------- -------- -------- ------ ---------
3 43,401,966 99.97% 11,044 0.03% 147,328
----------- -------- -------- ------ ---------
4 43,110,425 98.97% 448,742 1.03% 1,171
----------- -------- -------- ------ ---------
5 43,108,985 98.97% 450,182 1.03% 1,171
----------- -------- -------- ------ ---------
For further information please contact:
Trellus Health plc https://trellushealth.com/
Dr. Marla Dubinsky, CEO and Co-Founder Via Walbrook PR
Dr. Daniel Mahony, Chairman
Steve Young, CFO
Singer Capital Markets (Nominated Tel: +44 (0)20 7496 3000
Adviser and Broker)
Aubrey Powell / Jen Boorer
Walbrook PR Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / (0) 7748 651
Phillip Marriage 727 / (0)7867 984 082
About Trellus Health plc ( www.trellushealth.com )
Trellus Health (LSE: TRLS) is the first resilience based digital
health company focused on the intersection of chronic illness and
mental health. Trellus Health integrates its proprietary
resilience-based methodology with the technology, tools, and team
to deliver a whole-person technology-enhanced experience that
results in relieving disease burden, building self-management
skills and promoting positive health behaviours that improves
outcomes and enables thriving in the face of a chronic condition.
Through its TrellusElevate(TM) connected health platform and
companion App, the company addresses both physical and behavioural
health together, in context, to improve outcomes and reduce
healthcare costs across the healthcare ecosystem.
The Company was founded by Mount Sinai faculty members Marla C.
Dubinsky, MD and Laurie Keefer, PhD, both with over 50 years of
combined clinical and research experience in IBD, IBS and
psychogastroenterology, respectively.
The Company was initially focused on inflammatory bowel disease
("IBD"), which includes the chronic incurable conditions of Crohn's
Disease and ulcerative colitis but has now added Irritable Bowel
Syndrome ("IBS"). Given the common emotional and mental health
struggles often experienced by individuals suffering from a variety
of chronic conditions, Trellus Health considers its approach to
have potential utility and demand across many conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the GRITT(TM)
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. This proprietary, resilience-driven methodology has been
scientifically validated to demonstrate meaningful improvements in
patient outcomes, 71% reduction in Emergency Department (A&E)
visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health outcomes(1)
.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit: www.trellushealth.com
(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUUOUROVUNUAR
(END) Dow Jones Newswires
June 22, 2023 08:37 ET (12:37 GMT)
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Trellus Health (LSE:TRLS)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
